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To the Editor: 
Inhibiting tumor necrosis factor alpha (TNFα) has emerged as an effective therapy in inflammatory bowel 
diseases (IBDs)1 but an increased risk to develop reactivation of latent tuberculosis (TB) was observed soon after 
its introduction.2,3 Hence, exclusion of active TB and treatment of latent tuberculosis infection (LTBI) have 
become clinically imperative prior to starting anti-TNF treatment. Patients should be screened for prior TB 
exposure. Chest radiograph must be performed for active TB detection.4 Several guidelines have suggested a 
tuberculin skin test (TST) prior to anti-TNF therapy but a high risk of anergy is observed due to the use of 
immunosuppressive drugs. T-cell interferon gamma release assays (IGRAs) are more sensitive and more specific 
than TST and could become an alternative for detection of LTBI.5,6 After starting the anti-TNF therapy in 
patients with negative TST, no data are available concerning the risk of developing new TB infection under anti-
TNF treatment. In our daily practice we observed 2 cases of TST positivity after more than 1 year of anti-TNF 
therapy. 
The first case concerned a 34-year-old male suffering from Crohn's disease (CD) treated with azathioprine for 1 
year. A bitherapy with azathioprine and anti-TNF was then started. Prior to the infliximab therapy, clinical 
examination, chest x-ray, and TST using 5 units of tuberculin were normal. The patient had no history of TB 
exposure. The infliximab therapy was stopped after 4 years due to a loss of efficacy. Before switching to 
adalimumab treatment, the chest x-ray was normal. The patient, working as a prison guard, revealed a contact 6 
months earlier with a prisoner suffering from active TB. TSTs performed every year at the prison were negative 
but it became strongly positive before starting adalimumab. The patient had neither clinical nor radiological 
signs of active TB suggesting a contamination by LTBI. 
The second case was a 34-year-old female suffering from active ulcer-ative colitis (UC) despite corticosteroid 
and methotrexate therapy. Before infliximab treatment, the chest x-ray and the TST using 5 units of tuberculin 
were strictly negative. She had no history of TB exposure. The patient was treated with infliximab in mono-
therapy for 1 year. Because of a relapse 6 months later, adalimumab was proposed. At this time the chest x-ray 
and the clinical examination were normal. The patient had no history of recent TB exposure but she traveled 
recently to Rumania. The TST was repeated and revealed a large erythema and induration of 25 mm, suggesting 
a TB contamination without clinical or radiological signs of active BK. 
One-third of the world's population has LTBI that can potentially progress to active disease in 5%-10% of the 
cases.7,8 The risk of developing clinical manifestations is greatly increased in the case of immunosuppression as 
with anti-TNF therapy but the rate is not exactly known. In the literature, all the cases of active TB occurring 
under anti-TNF therapy are described as the consequence of the reactivation of an LTBI already present before 
the treatment. No case of de novo active TB or LTBI is described either  in  human  or  in  animal  models.9,10 
Our recent experience showed 2 TB contaminations in patients receiving long-term anti-TNF treatment. Despite 
its poor sensitivity in immunocompromised patients, the TST became highly positive in our 2 patients with a low 
risk of false positivity (no BCG vaccine, no endemic area for atypical mycobacterium). Moreover, the first had a 
well-documented contact with an infected prisoner and the second traveled in an endemic area for TB 
contamination. They had no clinical or radiologic sign of active TB suggesting the possibility of de novo LTBI. 
The rate of de novo LTBI under anti-TNF treatment and the risk of active TB are not documented. Screening 
anti-TNF treated patients for de novo LTBI by rigorous questioning, TST, or more sensitive tests like IGRAs 
could lead us to diagnose LTBI before active TB and to treat them effectively. These 2 cases highlight the risk of 
de novo TB contamination in anti-TNF-treated patients and question the optimal follow-up strategy of these 
patients. 
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